Literature DB >> 7559221

Combined hypoxia and hypercapnia evokes long-lasting sympathetic activation in humans.

B J Morgan1, D C Crabtree, M Palta, J B Skatrud.   

Abstract

We studied ventilatory and neurocirculatory responses to combined hypoxia (arterial O2 saturation 80%) and hypercapnia (end-tidal CO2 + 5 Torr) in awake humans. This asphyxic stimulus produced a substantial increase in minute ventilation (6.9 +/- 0.4 to 20.0 +/- 1.5 l/min) that promptly subsided on return to room air breathing. During asphyxia, muscle sympathetic nerve activity (intraneural microelectrodes) increased to 220 +/- 28% of the room air baseline. Approximately two-thirds of this sympathetic activation persisted after return to room air breathing for the duration of our measurements (20 min in 8 subjects, 1 h in 2 subjects). In contrast, neither ventilation nor sympathetic outflow changed during time control experiments. A 20-min exposure to hyperoxic hypercapnia also caused a sustained increase in sympathetic activity, but, unlike the aftereffect of asphyxia, this effect was short lived and coincident with continued hyperpnea. In summary, relatively brief periods of asphyxic stimulation cause substantial increases in sympathetic vasomotor outflow that outlast the chemical stimuli. These findings provide a potential explanation for the chronically elevated sympathetic nervous system activity that accompanies sleep apnea syndrome.

Entities:  

Mesh:

Year:  1995        PMID: 7559221     DOI: 10.1152/jappl.1995.79.1.205

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  69 in total

Review 1.  Resistant hypertension and sleep apnea: pathophysiologic insights and strategic management.

Authors:  Stephen K Williams; Joseph Ravenell; Girardin Jean-Louis; Ferdinand Zizi; James A Underberg; Samy I McFarlane; Gbenga Ogedegbe
Journal:  Curr Diab Rep       Date:  2011-02       Impact factor: 4.810

2.  Tetraplegia is associated with enhanced peripheral chemoreflex sensitivity and ventilatory long-term facilitation.

Authors:  Abdulghani Sankari; Amy T Bascom; Anas Riehani; M Safwan Badr
Journal:  J Appl Physiol (1985)       Date:  2015-08-13

Review 3.  Obstructive sleep apnea syndrome and asthma: what are the links?

Authors:  Michel Alkhalil; Edward Schulman; Joanne Getsy
Journal:  J Clin Sleep Med       Date:  2009-02-15       Impact factor: 4.062

Review 4.  Hypoxia-inducible factors and obstructive sleep apnea.

Authors:  Nanduri R Prabhakar; Ying-Jie Peng; Jayasri Nanduri
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808

5.  Reactive oxygen species contribute to sleep apnea-induced hypertension in rats.

Authors:  Carmen M Troncoso Brindeiro; Ana Q da Silva; Kyan J Allahdadi; Victoria Youngblood; Nancy L Kanagy
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-08-31       Impact factor: 4.733

6.  Postural change alters autonomic responses to breath-holding.

Authors:  Indu Taneja; Marvin S Medow; Debbie A Clarke; Anthony J Ocon; Julian M Stewart
Journal:  Clin Auton Res       Date:  2009-12-11       Impact factor: 4.435

Review 7.  Pathophysiology of sleep apnea.

Authors:  Jerome A Dempsey; Sigrid C Veasey; Barbara J Morgan; Christopher P O'Donnell
Journal:  Physiol Rev       Date:  2010-01       Impact factor: 37.312

8.  Firing probability and mean firing rates of human muscle vasoconstrictor neurones are elevated during chronic asphyxia.

Authors:  Cynthia Ashley; Danielle Burton; Yrsa B Sverrisdottir; Mikael Sander; David K McKenzie; Vaughan G Macefield
Journal:  J Physiol       Date:  2010-01-05       Impact factor: 5.182

Review 9.  Hypoxia-induced phrenic long-term facilitation: emergent properties.

Authors:  Michael J Devinney; Adrianne G Huxtable; Nicole L Nichols; Gordon S Mitchell
Journal:  Ann N Y Acad Sci       Date:  2013-03       Impact factor: 5.691

Review 10.  Chemoreflexes, sleep apnea, and sympathetic dysregulation.

Authors:  Meghna P Mansukhani; Tomas Kara; Sean M Caples; Virend K Somers
Journal:  Curr Hypertens Rep       Date:  2014-09       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.